Pancreatic Cancer Research

ResearcherNihon UniversityActive in the last 2 years

Hirofumi Kogure

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2355-7309; OpenAlex author ID A5062029828. Sources: OpenAlex.

Their work

Papers
35 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
35
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: 8 papers · 2014: 5 papers · 2015: 3 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 35

  1. Hemospray for Pancreatic Cancer-Related Gastric Bleeding. Last author DOI 10.2169/internalmedicine.8167-26↗
  2. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Co-author DOI 10.1007/s10637-020-00982-7↗
  3. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  4. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗
  5. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  6. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  7. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  8. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  9. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  10. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  11. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Co-author DOI 10.1007/s10637-016-0369-0↗
  12. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2016.05.016↗
  13. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  14. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  15. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  16. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  17. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  18. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Co-author DOI 10.1038/bjc.2014.131↗
  19. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Co-author DOI 10.1097/mpa.0000000000000158↗
  20. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. Co-author DOI 10.1111/jgh.12602↗
  21. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  22. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2278-7↗
  23. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  24. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  25. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  26. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  27. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Co-author DOI 10.1097/mpa.0b013e31825de678↗
  28. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  29. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Co-author DOI 10.1038/bjc.2012.183↗
  30. Incidental pancreatic cysts found by magnetic resonance imaging and their relationship with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31824f5970↗
  31. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Co-author DOI 10.1111/j.1349-7006.2012.02311.x↗
  32. Simultaneous Duodenal Metal Stent Placement and EUS-Guided Choledochoduodenostomy for Unresectable Pancreatic Cancer. Co-author DOI 10.5009/gnl.2012.6.3.399↗
  33. Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. Co-author DOI 10.1016/j.critrevonc.2010.05.007↗
  34. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2011.04.046↗
  35. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Co-author DOI 10.1159/000328767↗

Closest collaborators

The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yousuke Nakai · 34 shared papers, 2011–2021 · strength 1.47
  2. Kazuhiko Koike · 33 shared papers, 2011–2021 · strength 1.45
  3. Hiroyuki Isayama · 33 shared papers, 2011–2021 · strength 1.36
  4. Suguru Mizuno · 29 shared papers, 2011–2021 · strength 1.33
  5. Naminatsu Takahara · 25 shared papers, 2011–2021 · strength 1.22
  6. Minoru Tada · 31 shared papers, 2011–2019 · strength 1.16
  7. Tsuyoshi Hamada · 21 shared papers, 2011–2021 · strength 1.02
  8. Kei Saito · 13 shared papers, 2014–2021 · strength 0.84
  9. Hideaki Ijichi · 19 shared papers, 2012–2021 · strength 0.78
  10. Kazunaga Ishigaki · 10 shared papers, 2015–2021 · strength 0.71
  11. Tomotaka Saito · 9 shared papers, 2014–2021 · strength 0.63
  12. Saburo Matsubara · 15 shared papers, 2011–2019 · strength 0.60
  13. Takashi Sasaki · 18 shared papers, 2011–2015 · strength 0.53
  14. Naoki Sasahira · 17 shared papers, 2011–2015 · strength 0.46
  15. Koji Miyabayashi · 14 shared papers, 2012–2015 · strength 0.43
  16. Kei Saito · 1 shared paper, 2026 · strength 0.43
  17. Dai Mohri · 12 shared papers, 2011–2017 · strength 0.40
  18. Kazumichi Kawakubo · 11 shared papers, 2011–2015 · strength 0.30
  19. Keisuke Yamamoto · 10 shared papers, 2011–2015 · strength 0.29
  20. Tsuyoshi Takeda · 4 shared papers, 2015–2019 · strength 0.24
  21. Takashi Sasaki · 6 shared papers, 2011–2019 · strength 0.22
  22. Yukari Suzuki · 2 shared papers, 2020–2021 · strength 0.20
  23. Yasuyuki Seto · 1 shared paper, 2021 · strength 0.11
  24. Masao Omata · 5 shared papers, 2011–2012 · strength 0.11
  25. Takahiro Kishikawa · 2 shared papers, 2015–2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.